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Amyloid fibers and oligomers are associated with a great variety of human diseases including
Alzheimer’s disease and the prion conditions. Here we attempt to connect recent discoveries on
the molecular properties of proteins in the amyloid state with observations about pathological
tissues and disease states.We summarize studies of structure and nucleation of amyloid and relate
these to observations on amyloid polymorphism, prion strains, coaggregation of pathogenic
proteins in tissues, and mechanisms of toxicity and transmissibility. Molecular studies have also
led to numerous strategies for biological and chemical interventions against amyloid diseases.What Is the Amyloid State?
Many proteins enter the so-called amyloid state, in which they
form elongated fibers, with spines consisting of many-stranded
b sheets. The operational definition of amyloid, which has been
adopted by the community of pathologists, is that the fibers
are unbranched, usually extracellular, and found in vivo; in addi-
tion, the fibers bind the dye Congo Red and then show green
birefringence when viewed between crossed polarizers (Sipe
et al., 2010). By this definition, fewer than 25 amyloid-forming
proteins have been identified and associated with serious
diseases, including amyloid-b peptide (Ab) with Alzheimer’s
disease (AD), islet amyloid polypeptide (IAPP) with diabetes
type 2, and prion protein (PrP) with the spongiform encephalop-
athies.
Biophysicists prefer a molecular-based definition, and thus
they have abandoned the requirement that the fibers are usually
extracellular and disease associated. The reasons for this
change is that the same disease-related proteins form similar
fibers in vitro and many other proteins form similar fibers when
denatured (Fa¨ndrich et al., 2003) or during their physiological
roles (Chapman et al., 2002; Fowler et al., 2007; Si et al.,
2003). Accordingly, biophysicists have adopted a structure-
related definition for amyloid fibers, in which amyloid fibers
display the cross-b fiber diffraction pattern (Figure 1).
This pattern was first observed by the pioneering biophysicist
William Astbury (Astbury et al., 1935), who stretched a poached
egg white into a fiber in the X-ray beam. Astbury reasoned
correctly that in such fibers, elongated protein strands must be
stacked along the fiber axis, forming protein sheets that are
parallel to each other. A decade and a half later, Pauling and
Corey built models for these b sheets, showing that hydrogen
bonds hold the strands into sheets.
Proteinsmay enter the amyloid state when a segment exposes
its backbone amide N-H groups and C=O groups, permitting1188 Cell 148, March 16, 2012 ª2012 Elsevier Inc.them to couple into hydrogen bonds with other protein chains.
Several conditions produce exposed backbone amide groups:
denaturation of a normally folded protein (Chiti et al., 1999), over-
expression of a protein that overwhelms cellular chaperones and
drives it into an inclusion body (Wang et al., 2008), cleavage of
a peptide (such as Ab) from a folded protein, or over production
of a natively disordered protein (such as tau or IAPP). Exposure
of backbone amide groups is necessary for amyloid formation
but not sufficient. In addition, the local concentration of the
exposed segment must be sufficiently great to overcome the
entropy that opposes formation of ordered fibers. The higher
the concentration, the more aggregation is favored. Suppose
the concentration of the exposed segment is [P] and that of the
aggregated fiber of n units is [nP]. Then (neglecting intermediate
states) the free energy change for the process of aggregation is
given by
DG=DG0 +RT In
½nP
½Pn

;
in which DG0 is the standard free energy change for the reaction,
and RT is the product of the gas constant and the absolute
temperature. Because there are tens of thousands of protein
molecules in an amyloid fiber, that is n = thousands, [P]n
becomes large when the concentration of P goes up, and the
log of the ratio becomes extremely negative, meaning that the
free energy of amyloid formation is highly favorable.
In the laboratory, scientists can often produce amyloid fibers
from a protein at high concentration by partially denaturing it
with a destabilizing solvent, a change in pH, heating, or surface
denaturation from agitation. In cells and tissues, amyloid forma-
tion occurs with abnormally high expression of a protein. In
humans, we do not yet understand all causes of amyloid forma-
tion, but increased synthesis or reduced degradation of a given
Figure 1. Properties of Amyloid Fibers
(A) The characteristic cross-b diffraction pattern observed when X-rays are
directed on amyloid fibers. The diffuse reflection at 4.8 A˚ spacing along the
meridian (vertical) shows extended protein chains running roughly perpen-
dicular to the fibril and spaced 4.8 A˚ apart. The even more diffuse reflection at
10 A˚ spacing along the equator (horizontal) shows that the extended chains
are organized into sheets spaced 10 A˚ apart. For less well-oriented fibrils,
both reflections blur into circular rings.
(B) The steric-zipper structure of the sequence segment GNNQQNY from the
yeast prion Sup35. Five layers of b strands are shown of the tens of thousands
in a typical fibril or microcrystal. The front sheet shows the protein backbones
of the strands as gray arrows; the back sheet is in purple. Protruding from each
sheet are the sidechains. The arrow marks the fibril axis.
(C) The two interdigitating b sheets are viewed down the axis. Water mole-
cules, shown by red + signs are excluded from the tight interface between the
sheets. Red carbonyl groups and blue amine groups form hydrogen bonds up
and down between the layers of the sheet (Nelson et al., 2005).
(B) and (C) are reprinted from Nelson et al. (2005).protein, leading to an abnormally high concentration, is a factor
(Balch et al., 2008).
For amyloid to form, a nucleus must template the bonding
pattern of the fiber spine. As described in the section on the
structure of the amyloid spines, each fibril spine is built on an
intricate pattern of hydrogen bonds and steric interactions.
From the atomic structure of one such spine, it was suggested
that templating the pattern of the spine requires three or four
protein molecules (Nelson et al., 2005). If so, then three or four
molecules must expose their amyloid-forming segments at the
same time and must be at high enough concentration for
bonding and consequent templating of the fibril pattern. Thus,nucleation is a rare event, but once the nucleus is formed, single
molecules can join the growing fibril one at a time, as they open
to expose the proper segment and bond at the ends of fibrils. The
result is that amyloid fibril formation is characterized by a slow
nucleation phase, followed by amore rapid growth phase (Jarrett
and Lansbury, 1993). The pathway for amyloid fiber formation is
at present an active area of investigation with evidence that
fibers can form by nucleated conformational conversion from
an oligomeric state (Lee et al., 2011). Because fibrils grow from
their ends, breakage of fibrils affects the kinetics of fibrillar
growth (Tanaka et al., 2006), and a full description of fibril forma-
tion must include rates of nucleation, growth, and breakage
(Knowles et al., 2009).
Concepts of nucleation are important in understanding
amyloid and prion diseases. Nucleation is stochastic and the
chance for forming a nucleus is lowered as the volume of solution
is diminished. For example, a bottle of water can be supercooled
to only a few degrees Celsius before ice nucleates. However, as
its volume is diminished, water can be increasingly supercooled.
Micron-sized drops can be supercooled to 41C (Kuhns and
Mason, 1968). Biological cells are micron sized, and thus we
might expect that amyloid nucleation would be infrequent for
intracellular proteins, even when they are at relatively high
concentration. Of course, if we introduce a nucleus or ‘‘seed’’
from the outside to a supercooled liquid or a supersaturated
solution, growth on the nucleus is fast. For instance, try touching
an ice chip to the surface of a bottle of supercooled water.
Instant crystallization occurs because the ice chip provides the
nucleus, or an exact three dimensional pattern, of water mole-
cules in ice. Thus, the concept of seeding is important for under-
standing propagation of amyloid fibers or prions from cell to cell
or organism to organism.
What Is the Atomic Structure of the Amyloid Spine?
Amyloid fibers share a common ‘‘cross-b’’ spine. In 1959, elon-
gated, unbranched fibrils were reported in electron micrographs
of diseased tissues from diverse origins (Cohen and Calkins,
1959), and 9 years later X-ray diffraction patterns of such fibrils
were identified as Asbury’s cross-b type (Eanes and Glenner,
1968). With the advent of synchrotron X-ray radiation, scientists
found that amyloid fibers formed from six different proteins; each
one was associated with a different clinical syndrome and
showed similar cross-b diffraction (Sunde et al., 1997).
Determining the atomic details of the cross-b spine has been
slow because the limited order of fibrils, whether isolated from
diseased tissues or from in vitro conversion of native proteins
to the amyloid state, presents challenges to crystallographic,
nuclear magnetic resonance (NMR), and electron microscopy
(EM) methods. But important features have gradually emerged
from studies by solid-state NMR (Benzinger et al., 1998; Tycko,
2011), model-building constrained by X-ray fiber and powder
diffraction (Makin et al., 2005; Sunde and Blake, 1998), site-
directed spin labeling (Serag et al., 2001; To¨ro¨k et al., 2002),
cryo-EM (Jime´nez et al., 1999; Schmidt et al., 2009), scanning
mutagenesis (Williams et al., 2004), and single-crystal X-ray
diffraction (Nelson et al., 2005). The most general points to
emerge are that (1) in all amyloid fibers, the strongest repeating
feature is a set of b sheets that are parallel to the fibril axis,Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1189
with their extended strands near perpendicular to the axis; (2) the
b sheets can be either parallel or antiparallel, that is, adjacent
hydrogen-bonded b strands within a sheet can run in the same
direction or in opposite directions; and (3) the sheets are usually
‘‘in register,’’ meaning that strands align with each other such
that identical side chains are on top of one another along the fibril
axis. In parallel sheets, identical side chains are separated by an
interstrand distance of 4.8 A˚ (Figure 1), and in antiparallel sheets,
they are separated by 2 3 4.8 A˚ = 9.6 A˚.
The architecture of at least the simplest cross-b amyloid
spines has been clarified by determining short segments of
amyloid-forming proteins (Apostol et al., 2010; Ivanova et al.,
2009; Nelson et al., 2005; Sawaya et al., 2007; Sievers et al.,
2011; Wiltzius et al., 2009). The segments examined are those
that seem to be the adhesive parts of amyloid proteins. In isola-
tion from the rest of the protein, they form microcrystals and
related fibers with morphological similarity to fibers of the entire
parent proteins (Balbirnie et al., 2001). The atomic structures of
the microcrystals reveal that the motif of the amyloid protofila-
ment consists of a pair of b sheets that run the length of the
fiber-like crystals (Figure 1B). Each sheet is a standard Paul-
ing-Corey b sheet, in which each strand is hydrogen bonded to
the strand above and below it through its backbone amide
groups.
When the side chains contain amides (glutamine and aspara-
gine), those amides also form hydrogen bonds to the identical
residue in the strands above and below. This creates parallel
arrays of hydrogen bonds running along the fiber axis. The elec-
trostatic interactions of all of these aligned hydrogen bonds
mutually polarize one another, producing hydrogen bonds
even stronger than those in ice (Tsemekhman et al., 2007). The
stability of such interdigitated b sheets explains the persistence
of amyloid fibers and prions.
Within the protofilament, the side chains emanating from the
two sheets are tightly interdigitated, as shown in Figure 1C,
like the teeth of a zipper. The interface between the sheets is
devoid of water, and hence this motif has been termed the
‘‘dry steric zipper.’’ Dozens of atomic structures of dry steric
zippers have been determined by X-ray crystallography and
share the following properties: (1) Steric zippers form from self-
complementary amino acid sequences, in which their sidechains
can mutually interdigitate. The sequences can be polar or
nonpolar, with large side chains or small, but they fit together
in complementary fashion. (2) Steric zippers have dry interfaces
between the two sheets. Thus, the hydrophobic effect contrib-
utes to amyloid stability, as does the strong hydrogen bonding.
(3) The b strands are most often in register, maximizing inter-
strand hydrogen bonding and permitting stacking of glutamine
(Gln), asparagine (Asn), and tyrosine (Tyr) residues. Although all
steric zippers are expected to be formed from complementary
sequences, the sequences do not need to be self-complemen-
tary. There is strong evidence from solid-state NMR studies
(Lu¨hrs et al., 2005; Petkova et al., 2002) that in Ab, some close
interactions are between b strands that differ in sequence (see
Figure 4). Such ‘‘heterosteric zippers’’ have not yet been
observed in X-ray crystal structures.
The most common sheet-to-sheet arrangement for steric
zippers is face to face (class 1; Figure 1B), but other arrange-1190 Cell 148, March 16, 2012 ª2012 Elsevier Inc.ments occur (Figure 2). In these other arrangements, the two
sheets can be face to back (classes 2 and 4), pack with opposite
edges up rather than both edges up (class 4), or contain antipar-
allel strands (classes 5–8), rather than parallel strands (classes
1–4) (Sawaya et al., 2007). To date, no examples in class 3
have been observed.
Some amyloid spines are more complex than single steric
zippers. For instance, several different steric zippers all formed
by the same protein can occur in the spine. In fact some 13
different steric zippers have been found for the 42-residue
sequence of Ab (Colletier et al., 2011). Many proteins, including
the PrP and Sup35 prions, Ab, and IAPP, have several potential
steric zipper-forming segments within their sequences. In
a recent report, Lewandowski et al. (2011) provide solid-state
NMR evidence that fibers of the yeast prion Sup25 contain three
distinct steric zippers (one is shown in Figure 1B).
A second source of increased complexity is the likelihood of
heterozippers formed from cross-complementary sheets. Heter-
ozippers have been found by solid-state NMR in the structure of
Het-s, a fungal prion (Wasmer et al., 2008) (Figure 3). This struc-
ture, termed a solenoid by its discoverers, consists of a stack of
two-layer protein loops. Each loop contains two extended
strands with their side chains interdigitating in a similar manner
as those in a steric zipper. Each molecule of Het-s contributes
two such loops that stack on top of each other. This pair of loops
then stacks on top of, and beneath, pairs of loops from its adja-
cent molecules in the fiber. The entire structure is amyloid like.
The b sheet interactions in Het-s have been selected by evolu-
tion, in contrast to some interactions that are found in the
spontaneous aggregation of disease-related proteins. Hetero-
zippers probably are also found in spontaneous aggregates of
proteins, such as those of Ab, but they have not yet been fully
defined at high resolution.
What Is the Structure of Protein Segments Outside
of the Amyloid Spine?
Althoughwe have atomic structures for some amyloid spines, we
do not yet have full atomic structures for whole amyloid fibrils.
Full amyloid fibrils are more complicated than the simple spine
structures in that some fibrils appear to contain numerous proto-
filaments and are complex in structure (Lewandowski et al.,
2011; White et al., 2009).
The findings about amyloid spines (see the section on the
structure of the amyloid spines) place severe constraints on fibril
models. Given that proteins stack in register with strands spaced
4.8 A˚ along the fibril axis, the rest of the protein must be flattened
out so that each layer is only 4.8 A˚ high or must somehow sit at
the periphery of the spine, where it may extend more than 4.8 A˚
along the axis, avoiding overlap with identical domains. A flat-
tened model for Ab is shown in Figure 4A, based on solid
state-NMR measurements (Tycko, 2011). Each Ab molecule
makes a U-turn, called a b arch (Kajava et al., 2010). For longer
proteins, it has been proposed that U turns are linked into
a serpentine structure, termed a superpleated b structure (Fig-
ure 4B) (Kajava et al., 2010). In a superpleated b sheet, the entire
protein chain is flattened to fit in one 4.8 A˚ layer of the fibril.
Flattening is not necessary for an amyloid-forming protein to
retain globular domains. In the model of a designed amyloid of
Figure 2. Steric-Zipper Protofilaments
Twenty-eight atomic structures of steric-zipper protofilaments from amyloid-forming proteins, determined by X-ray diffraction. All are viewed projected down the
protofilament axis, revealing the two sheets (one ivory and one blue) with their interdigitated sidechains. Selected zippers are also viewed perpendicular to
the protofilament axis, with five layers of b strands shown with backbones as arrows. Water molecules are shown as aqua spheres; notice their absence from the
interfaces between the paired sheets.RNase A (Figure 4C), the domains on the periphery of the spine
find space to retain their globular structure (Sambashivan et al.,
2005). For larger globular domains, a greater circumference of
the fibril and a longer protein linker to the steric zipper is required.
This means that fibers formed from larger proteins would be ex-
pected to have greater diameters. In short, although the spines
of amyloid fibers appear similar, fibrils show a great variety of
structural complexity.
What Is the Basis of Amyloid Cross-Seeding?
The observation that amyloid fibrils have spines composed of
steric zippers explains why different proteins, when they enter
the amyloid state, give fibrils of similar appearance in electron
micrographs. The fibrils are all elongated and unbranched, just
as their steric-zipper spines are elongated and unbranched.The diameters of the fibrils vary because the lengths of the
proteins that form them differ and because the number of proto-
fibrils that twist around each other to form the fibril may differ.
Thus, we would expect that cross-seeding of amyloid fibril
formation in which the seed is formed from another, but similar,
amyloid fibril is possible. All steric zippers formed from parallel
b strands have one repeat the same: 4.8 A˚ in the fibril axis direc-
tion; similarly, all antiparallel zippers have one repeat the same:
9.6 A˚ in the fibril axis (Figure 1). If the seeding steric zipper is
complementary in shape to a segment of the seeded protein in
solution, we could expect a heterosteric zipper to form and to
serve as a nucleus, as has been shown in vitro for Ab and IAPP
(Andreetto et al., 2010).
In yeast, cross-seeding has been suggested as the mech-
anism for the observation that one prion can induce theCell 148, March 16, 2012 ª2012 Elsevier Inc. 1191
Figure 3. Structure of a Heterozipper
The solid-state NMR-derived structure of Het-s shows heterozippers (Wasmer
et al., 2008).
(A) The protein chain of eachmolecule (in a single color) contains six b strands,
organized in double loops. The double loops of adjacent molecules sit on top
of one another, hydrogen bonded up and down.
(B) The two layers are shown schematically with sidechains represented as
circles. Each layer may be regarded as a hetero-zipper, in which the sidechains
of opposing strands interdigitate.
The figure is reprinted from Wasmer et al. (2008).appearance of another (heterologous) prion. However, heterolo-
gous prion interactions can also inhibit prion propagation
(Bradley et al., 2002). Similar observations have been made
with mammalian prions that can either promote or inhibit PrP
aggregation (Nilsson et al., 2010). Cross-seeding and cross-inhi-
bition in vivo also has been reported between ApoAII amyloid
(AApoAII) and serum amyloid A (AA) fibrils (Yan et al., 2007).
Moreover, AA amyloid can be cross-seeded in susceptible
mice with heterologous b-rich proteins (Lundmark et al., 2005).
While cross-seeding presumably results from formation of a
heterozipper, cross-inhibition might result from a capping of fibril
ends, a principle used to develop amyloid interfering compounds
(see the section on inhibition of amyloid).
In human neurodegenerative diseases, the coexistance of
more than one amyloid deposit is a common observation. For
example, in Gerstmann-Stra¨ussler-Scheinker Syndrome, coloc-
alization of APrP and Ab in the same amyloid plaque has been
described (Miyazono et al., 1992). Similarly, in Familial Danish
Dementia Ab and Danish amyloid (ADan) colocalize in paren-
chymal and vascular amyloid deposits (Tomidokoro et al.,
2005). In Parkinson-related diseases, a-synuclein and tau inclu-
sions can occur in the same cell and form common inclusion
bodies (Giasson et al., 2003). Although cross-seeding provides
an attractive explanation for these observations (Giasson et al.,
2003; Morales et al., 2010), definitive proof is lacking, and other
explanations are possible. For example, (1) two amyloid deposits
may simplydevelop independently of eachother; (2) theremaybe
saturable cellular fractions for the removal of misfolded proteins,
and thus one aggregated protein may indirectly stimulate1192 Cell 148, March 16, 2012 ª2012 Elsevier Inc.aggregation of further proteins bymonopolizing clearancemech-
anisms; and, (3) colocalization of two amyloids is only apparent at
the light-microscopic level and reflects common cellular niches
prone to protein aggregation, while at the ultrastructural level,
true coaggreagtion of the two amyloids may not occur. Yet other
observations indicate that the interaction of amyloidogenic
proteins in human brain can impede, rather than promote, aggre-
gation. For example, cystatin C colocalizes with Ab plaques in
Alzheimer’s disease, but the finding that cystatin C reduces Ab
plaque formation in transgenic mice suggests a mechanism of
cross-inhibition rather than cross-seeding (Kaeser et al., 2007).
What Are Amyloid Polymorphisms and Amyloid Strains?
The term ‘‘strain’’ is used by microbiologists to denote structur-
ally or functionally variant microbes within a given species. Simi-
larly, prion strains inmammals have been assumed to be variants
of PrP aggregates that exhibit characteristic biological proper-
ties (Aguzzi et al., 2007; Colby and Prusiner, 2011; Collinge
and Clarke, 2007). Whereas the genotype of a microbial strain
is encoded by its nucleic acid sequence, that of a prion strain
is encoded by the ‘‘conformation’’ of PrP (Colby and Prusiner,
2011; Collinge and Clarke, 2007; Prusiner, 1982). The formation
of structurally distinct, polymorphic protein fibers is now recog-
nized as a common property of amyloid-forming proteins (Chiti
and Dobson, 2006; Goldsbury et al., 2005; Tanaka et al.,
2006). For example, synthetic Ab can aggregate into structurally
diverse amyloid fibrils, which retain their conformational proper-
ties and cellular toxicities after repeated passage (Petkova et al.,
2005).
Hypotheses for the Conformational Basis of Amyloid
Strains
Three models for the molecular basis of prion strains and
amyloid poymorphs have been proposed on the basis of atomic
structures of amyloid-like fibers (Figure 2). The models suggest
that strains are based in distinct steric-zipper spines of the asso-
ciated amyloid fibers. The first model is termed packing polymor-
phism and is illustrated in Figure 2 by the pairs of zippers
connected by double-headed arrows. In packing polymorphism,
an amyloid segment packs in two or more distinct ways,
producing fibrils with different structures and distinctive proper-
ties. The simplest form of packing polymorphism is a registration
shift in which the two sheets forming the steric zipper in
the second polymorph shift their interdigitation from that in
the zipper of the first polymorph. Because the nature and posi-
tion of the side chains on the outer surface of the fibers differ
in the two polymorphs, the properties of the fibers must be
different (Greenwald and Riek, 2010; Wiltzius et al., 2009).
Thus, in packing polymorphism, one sequence forms two or
more ‘‘conformations.’’
The second structural model for strains is termed segmental
polymorphism. In segmental polymorphism, two or more
different segments of an amyloid protein are capable of forming
steric-zipper spines. Figure 2 shows two segments from Ab that
form different steric zippers. Fibrils formed with different steric-
zipper spines will each have distinctive properties. Proteins
particularly rich in different segments able to form steric zippers
include Ab (Colletier et al., 2011), IAPP (Wiltzius et al., 2009) and
PrP (Sawaya et al., 2007).
Figure 4. Models for Amyloid Fibrils Larger
than a Single Steric-Zipper Spine
(A) Model for Ab1-40 based on solid-state NMR
data with additional constrains from electron
microscopy (Tycko, 2011). The view is down the
fibril axis, showing two molecules of Ab, each with
a U turn or ‘‘b arch.’’ Where the green segments of
the two molecules abut, they appear to form
a homosteric zipper (class 1 in Figure 2), and
a heterozipper could exist between the two arms
of each U. Both types of steric zipper need to be
confirmed by higher-resolution structures.
(B) A proposed structure for longer amyloid
proteins is a ‘‘superpleated b structure’’ (Kajava
et al., 2010), in which the protein chain forms
several U turns/b arches. The view of the upper
diagram is down the fibril axis; the view of the
lower is perpendicular to the fibril axis. In the lower
diagram, each protein chain is hydrogen bonded
to the ones above and below (not shown). Heter-
ozippers may exist between pairs of differently
colored b strands. This type of structure has been
proposed for several proteins in the amyloid state
including Ure2p, Sup35p, and a-synuclein.
(C) Amodel for a designed amyloid of ribonuclease
A with ten glutamine residue inserted between the
core and C-terminal domains (Sambashivan et al.,
2005) based on X-ray and electron microscopy
data and steric constraints. The view is perpendicular to a cut-away of the fibril. The twisting steric zipper can be seen at the center. Globular subunits of
ribonuclease A, which are essentially in their native conformation, are at the periphery. The amyloid-like fibrils of this designed amyloid show enzymatic activity,
confirming that ribonuclease molecules retain native-like structure.In a third type of amyloid polymorphism, heterosteric zippers,
the zipper is formed from the interdigitation of nonidentical
b sheets. Though not yet seen in X-ray structures at the atomic
level, heterotypic interactions between sheets are observed in
the constrained models derived from solid-state NMR and
cyro-EM (Greenwald and Riek, 2010; Schmidt et al., 2009;
Tycko, 2011). The existence of such heteroamyloid spines, in
addition to self-complementary spines, greatly increases the
number of potential amyloid polymorphs and prion strains.
The hypothesis that distinct steric-zipper structures are at the
basis of amyloid fiber polymorphism and prion strains is consis-
tent with other observations about steric zippers. Steric zippers
can be extremely stable. For example the steric-zipper formed
by the segment of Sup35 with amino acid sequence GNNQQNY
could not be dissolved by 5% SDS nor by 4M urea; dissolution
required 100% formic acid, 4M guanidinium hydrocholoride, or
0.5 M NaOH (Balbirnie et al., 2001). Thus, steric zippers share
with prion strains robust ‘‘conformations’’ that can conceivably
be transmitted from cell to cell or organism to organism. Another
similarity between steric zippers and prion strains is that environ-
mental conditions seem to affect the formation of both. For
example, incubation of the yeast prion Sup35 at either 4C or
37C produces different prion strains in yeast (Tanaka et al.,
2004). Similarly, the differing steric zippers formed from the
same protein segment in Figure 2 were created by incubating
the segments under different solution conditions.
Amyloid Morphotypes
In the brain, Ab deposits are heterogeneous in histopathological
appearance and biochemical composition, both within and
among brain regions and patients (Maarouf et al., 2008; Tekirian
et al., 1998; Thal et al., 2006). Ab aggregation can occur in asso-
ciation with the vasculature or in the brain parenchyma asamyloid plaques. Point mutations within the Ab sequence can
lead to vascular amyloid, amyloid plaques, or both (Herzig
et al., 2006). Vascular and parenchymal Ab deposits differ in
the ratio of deposited Ab ending at amino acid 40 to Ab ending
at amino acid 42 (Herzig et al., 2006). Plus, the Ab40:Ab42 ratio
has been linked to different neurotoxicities and clinical Alz-
heimer’s disease onset (Duering et al., 2005; Kumar-Singh
et al., 2006; Kuperstein et al., 2010). In addition, Ab displays
length variations due to truncations at the N terminus (e.g., Ab
starting at residue 3, 11, or 17) and variations in posttranslational
modifications (e.g., isomerization, pyroglutamyl formation, phos-
phorylation, or nitration). All these factors can profoundly
influence Ab aggregation and histopathological appearance of
the amyloid (De Strooper, 2010; Kumar et al., 2011; Kummer
et al., 2011; Miravalle et al., 2005; Tekirian et al., 1998). A
predominance of N-truncated and posttranslationally modified
Ab distinguishes Ab deposits in Alzheimer’s disease compared
to normal aging and mouse models (Kuo et al., 2001; Piccini
et al., 2005). Although it remains difficult to study the conforma-
tional state of Ab in vivo, indirect measures with luminescent
conjugated polythiophene probes that detect particular amyloid
conformations suggest the occurrence of conformationally
distinct Ab deposits in brain (Nilsson et al., 2007) (Figure 5). Lumi-
nescent conjugated polythiophenes have also been used to
discriminate prion strains (Sigurdson et al., 2007).
Different Ab morphotypes in the brain may indicate that local
factors influence the Ab aggregates. They may also represent
various stages in the disease process (Thal et al., 2006) or reflect
the templated propagation of conformationally distinct seeds
(Levine and Walker, 2010). Although these possibilities are not
mutually exclusive, the third explanation has gained momentum
by the finding that Ab morphotypes can be transmitted toCell 148, March 16, 2012 ª2012 Elsevier Inc. 1193
Figure 5. Rainbow Amyloid
Novel amyloid dyes can be used as surrogate probes of the supramolecular
structure of protein aggregates. Shown are Ab plaques (yellow) and Ab amyloid
angiopathy (green) in an AbPP-transgenic mouse (carrying the AbPP Swedish
and AbPP Dutch mutation). Note the different spectral signatures upon
staining with the luminescent conjugated polythiophene tPTAA (bottom left).
The image was recorded using a combination of green and red filters. The
scale bar represents 20 mm.
Table 1. Familial Human Amyloid Diseases in which Mutations
Promote the Formation of Amyloid
Disease Variant Protein Amyloid
Alzheimer’s disease AbPP, PS1/2 Ab
Hereditary cerebral hemorrhage
with amyloidosis, Dutch type
AbPP Ab
Hereditary cerebral hemorrhage
with amyloidosis, Icelandic type
Cystatin C ACys
Familial British Dementia BriPP ABri
Familial Danish Dementia BriPP ADan
Parkinson’s disease a-synuclein ASyn
Frontotemporal lobar
degeneration (FTLD)-tau
Tau ATau
Gerstmann-Stra¨ussler-Scheinker PrP APrP
Creutzfeldt-Jacob Disease PrP APrP
Amyotrophic lateral sclerosis SOD1 ASOD1
Transthyretin familial amyloidosis TTR ATTR
Hereditary lysozyme amyloidosis Lysozyme ALys
Hereditary fibrinogen a-chain
amyloidosis
Fibrinogen
a-chain
AFib
Hereditary ApoAI/II amyloidoses Apolipoprotein
AI/II
AApoAI/II
Finnish hereditary amyloidosis Gelsolin AGeltransgenic mice overexpressing the Ab precursor protein (AbPP)
in vivo (Meyer-Luehmann et al., 2006). These observations are
reminiscent of previous transmission studies using transgenic
mice that overexpress PrP and deposit PrP amyloid (Peretz
et al., 2002), suggesting that the characteristics of prion strains
may also apply to multimeric Ab. However, the link between Ab
conformational variants and distinct clinical subtypes of
b amyloidoses is still lacking.
Hetereogeneous amyloid morphotypes are also observed in
other amyloidoses. Transthyretin (TTR) amyloid deposits show
variations in fibrils made of full-length versus C-terminal frag-
ments of TTR (Bergstro¨m et al., 2005), and in familial cases,
TTR amyloid deposition varies in the ratio of incorporated
wild-type versus mutant TTR (Ihse et al., 2011; Ihse et al.,
2008). Strikingly, such amyloid heterogeneity is associated
with the organ tropism (i.e., that the amyloid preferentially
deposits in particular organs) and clinical manifestation of TTR
amyloidoses (Westermark and Westermark, 2010). Similarly,
length variants of the AA protein characterize two different histo-
pathological AA amyloid patterns in the kidney with distinct
clinical phenotypes (Westermark et al., 1989). In the brain, tau
and a-synuclein inclusions reveal histopathological heteroge-
neity that is diagnostic of the various tauopathies and a-synu-
cleinopathies, respectively (Goedert et al., 2010). Consistently,
a-synuclein and tau fibrils in vitro exhibit conformational diver-
sity (Frost et al., 2009; Heise et al., 2005). Although recent
studies have reported the remarkable transmission of disparate
proteopathic lesions in transgenic mice (see the section on
amyloid transmission), solid evidence for the hypothesis that
the heterogeneous disease phenotypes are the result of the
(prion-like) templated conversion of conformationally distinct
TTR, AA, tau, and a-synuclein seeds is still lacking.1194 Cell 148, March 16, 2012 ª2012 Elsevier Inc.Amyloid Toxicities and Animal Models
Not all amyloids are toxic. First described in bacteria, fungi, and
yeast, and more recently in mammals, amyloids can function in
the formation of biofilms, the binding and storage of peptide
hormones, the formation of melanin formation, or the launch of
an antiviral innate immune response (Chapman et al., 2002;
Fowler et al., 2007; Hou et al., 2011; Maji et al., 2009). The type
of amyloid and the controlled growth conditions may account
for the lack of toxicity of so-called functional amyloids (Green-
wald and Riek, 2010; Watt et al., 2011).
However, most amyloid formation in mammals occurs
with aging and is associated with diseases commonly referred
to as protein misfolding diseases, aggregation diseases,
proteopathies, or, more specifically, amyloid diseases or
amyloidoses (Chiti and Dobson, 2006; Selkoe, 2003). An asso-
ciation of a given amyloid with a disease does not necessarily
denote causality. However, a causal relationship between the
amyloid formation and amyloid toxicity is suggested from
familial cases in which a pathogenic mutation leads to an
overproduction of the amyloidogenic protein or enhances
the propensity of the protein to aggregate (Table 1). It re-
mains unclear which step of the amyloid formation cascade is
toxic, and this step may be different for the various amyloid
diseases.
Amyloid toxicity can result from losing the function of a protein
or from the sequestration or mislocation of other proteins (Olz-
scha et al., 2011). This latter mechanism may be the toxicity
mechanism for the RNA-binding proteins TDP-43 and FUS
(Mackenzie et al., 2010), although at present their classification
as amyloids is uncertain. However, for most amyloid diseases,
a gain of toxic function remains a favored hypothesis.
Figure 6. Histopathology of Cerebral b Amyloidosis
(A) Ab immunostaining (brown) reveals severe cerebral amyloid angiopathy (CAA) in superficial cortical vessels in a human case.
(B) Ultrastructural analysis of Ab fibrils (af) in the vessel wall of an arteriole with CAA. Note that the amyloid has displaced nearly the entire vascular wall, disrupting
normal vessel-neuron communications (b, basal lamina; e, endothelial cells; l, lumen; m, media). Reprinted with permission from Yamada et al. (1987).
(C) Ab immunostaining (brown) of an amyloid plaque in a human Alzheimer’s disease case. Note the dense amyloid core and glial nuclei (blue) surrounded by
a halo of diffuse Ab immunostaining.
(D) Ultrastructure of an Ab plaque. Note the dense amyloid core with the amyloid fibrils (af) surrounded by numerous dystrophic neuritis (some are labeled with
‘‘dn’’). The Ab plaque is from an AbPP-transgenic mouse brain due to better tissue preservation compared to postmortem human tissue. Scale bars represent
100 mm (A), 1 mm (B), 50 mm (C), and 5 mm (D).In Search of the Toxic Amyloid Species
Despite the longstanding knowledge that amyloids are associ-
ated with disease (Cohen and Calkins, 1959), we still lack a clear
understanding of how amyloids lead to dysfunction, aside from
the instances in which amyloids disrupt tissue structure and
organ function via simple mass action (Pepys, 2001; Wester-
mark, 2005). This mass action mode of toxicity may well be the
most important one for most systemic amyloidoses and for the
amyloid associated with the cerebral vessels (cerebral amyloid
angiopathy, CAA) (Figure 6). CAA of various types (Ab, ADan,
British amyloid [ABri], and Cystatin C amyloid [ACys]) all result
in a thickening of the vascular basal lamina, loss of smooth
muscle cells, perivascular inflammation, and, eventually, vessel
wall rupture and hemorrhages (Revesz et al., 2009). Similar
appearances and toxicities of CAA (independent of the amyloid
type) are also seen in Ab- and ADan-transgenic mouse models
(Calhoun et al., 1999; Coomaraswamy et al., 2010). Moreover,
correlations between CAA severity and hemorrhage frequency
was found in humans and mouse models, suggesting that the
mass of amyloid fibrils may be the most important parameter
mediating vascular toxicity (Dierksen et al., 2010; Maeda et al.,
1993; Winkler et al., 2001).
Other amyloid deposits may not be the predominant toxic
entity per se. In Alzheimer’s disease autopsy material, the
soluble Ab species correlate more strongly with the degree of
dementia than does the mass of Ab plaques (Haass and Selkoe,
2007). Indeed, a variety of soluble Ab multimeric species (e.g.,
dimers, timers, dodecamers, and larger oligomers) have been
isolated from the Alzheimer’s disease brain, and they inducesynaptic toxicity and dysfunction, both in cell culture and when
injected into the rodent brain (Lesne´ et al., 2006; Shankar
et al., 2008). Similarly, synthetic, multimeric Ab appears to be
more toxic than Ab monomers or fibrils (Haass and Selkoe,
2007; Lambert et al., 1998; Ono et al., 2009), but it is often
unclear how the synthetic Ab species relate to the in vivo coun-
terparts (Meyer-Luehmann et al., 2006; Paravastu et al., 2009).
Also, for tau and a-synuclein, soluble oligomeric species appear
to be more toxic than the corresponding amyloid fibrils (Haass
and Selkoe, 2007; Spires-Jones et al., 2011; Winner et al., 2011).
The physicochemical properties of the toxic oligomeric
species are not well understood, and a consistent nomenclature
is needed (Glabe, 2008). It is generally assumed that the greater
toxicities of oligomers are mediated by their unique structural
features (Campioni et al., 2010). The higher relative toxicity of
small soluble oligomeric species, however, may also mirror the
greater diffusion capability of such small aggregates through
the tissue and into various compartments. Along the same lines,
the relatively lower toxicity of amyloid fibrils may reflect the fact
that many of the toxic structural entities of the fibril are buried in
the amyloid mass (Haass and Selkoe, 2007; Keshet et al., 2010).
For Ab toxicity, both receptor-mediated interactions and non-
receptor-mediated membrane interactions have been described
(Roychaudhuri et al., 2009; Yankner and Lu, 2009). The most
significant toxicity of Ab is toward the synapse. This is consistent
with the profound loss of synapses in the Alzheimer’s disease
brain and the observation that oligomeric Ab species inhibit
LTP, an electrophysiological correlate of memory formation
(Shankar and Walsh, 2009). Soluble Ab species bind toCell 148, March 16, 2012 ª2012 Elsevier Inc. 1195
postsynaptic structures and interact with various putative
ligands, such as PrP, NMDA receptor, EphB2, or downstream
signaling events (Cisse´ et al., 2011; Lacor et al., 2007; Laure´n
et al., 2009; Snyder et al., 2005; Wei et al., 2010), but their in vivo
relevance for Alzheimer’s disease pathogenesis is still unclear.
Non-receptor membrane cytotoxicity for Ab has been suggested
through the insertion of Ab oligomers into membranes, resulting
in membrane disruption, possibly with the formation of cation-
sensitive ion channels and dysregulation of calcium homeostasis
(Glabe and Kayed, 2006; Roychaudhuri et al., 2009). Similar
observations have been made with other oligomeric amyloid
intermediates, suggesting that membrane disruption may be
a more general mechanism in which amyloidogenic proteins
exert their toxicity (Glabe and Kayed, 2006; Hebda andMiranker,
2009; Stefani, 2010).
Nevertheless, bona fide amyloid lesions in the brain, such as
Ab plaques, neurofibrillary tangles, and Lewy bodies, are not
benign and are probably in equilibrium with their soluble protein-
aceous constituents. For example, Ab plaques are responsible
for local neuritic dystrophy (Figure 6), gliosis, and can eventually
lead to disturbed neural network activity (Hedden et al., 2009;
Tsai et al., 2004). Ab plaques may also serve as a source of the
more toxic and soluble Ab assemblies, consistent with the
view that a dynamic continuum of the various amyloid intermedi-
ates, not a given protein entity, elicits toxicity (Jan et al., 2011;
Martins et al., 2008; Selkoe, 2011; Wogulis et al., 2005)
The Value of Animal Models of Human Amyloid Diseases
Spontaneous amyloidoses do not occur in typical laboratory
animals, with the exception of ApoAII amyloidoses in some
genetically defined mouse strains (Higuchi et al., 1993). Aged
nonhuman primates and some other higher order mammals
can develop b amyloidosis and tau fibrillary inclusions in the
brain; however, these animals do not develop the clinical signs
of the human diseases (Jucker, 2010). Aged vervet monkeys,
but not other nonhuman primates, can spontaneously develop
TTR amyloidosis. In vervet monkeys, spontaneous amyloidosis
has been linked to the TTR lle122 allelic variant, which is also
a disease-causing mutation in humans (Ueda et al., 2011). AA
amyloidosis caused by inflammation or infection does occur in
animals (Gruys, 2004).
Currently used animal models of amyloidoses are largely
confined to genetically engineered mouse models. Most models
bear transgenes that overexpress the amyloidogenic human
protein, or, more often, its mutant counterpart that characterizes
the familial forms of the disease (Table 1). This transgene
approach has successfully modeled most cerebral amyloidoses
(including b amyloidosis, tauopathies, a-synucleinopathies, and
prion diseases) and systemic amyloidoses (such as TTR, gelso-
lin, and IAPP amyloidosis) (Buxbaum, 2009; Jucker, 2010; Page
et al., 2009; Wadsworth et al., 2010). In all cases, overexpression
of the amyloidogenic human protein appeared necessary
because mice with a simple knock-in of the human amyloido-
genic proteins do not spontaneously develop amyloid.
These mouse models have been extremely valuable for the
understanding of the amyloid aspect of the diseases, although
the models rarely fully recapitulate the clinical phenotype and
neurodegeneration observed in humans. Nevertheless, the
models have been successfully used to evaluate preclinical1196 Cell 148, March 16, 2012 ª2012 Elsevier Inc.amyloid-modifying therapies (Jucker, 2010). Moreover, the
incompleteness of most mouse models in recapitulating the
entire spectra of the human disease has often been helpful for
deciphering and understanding the complexity of the pathome-
chanisms of the diseases (Jucker, 2010).
Can Amyloid Formation Be Inhibited?
Chemical Interventions
Discovery of chemical interventions against amyloid conditions
have taken at least four different paths. One of the most prom-
ising paths is stabilization of the structure of the soluble form
of a protein, diminishing the rate at which it is likely to undergo
conversion to the amyloid state. The pioneering demonstration
of this strategywas on TTR (Johnson et al., 2012). TTR is a homo-
tetramer that carries serum retinol binding protein and thyroid
hormones, such as thyroxine. In several amyloid diseases, one
of many mutations can destabilize TTR, leading to fibrous
deposits in the heart and peripheral nerves. Using structure-
based design, several potent and specific binders to the
TTR hormone pocket have been described that inhibit fibril
formation (Klabunde et al., 2000). The same strategy could be
applied to other amyloid forming proteins that have a stable
native structure.
A second approach is to screen for small molecules that
disrupt fibril and oligomer formation. This enormous topic is
worthy of a review on its own. Writing in 2007, Necula et al.
(2007) list 16 screening studies for molecules that inhibit fibrils
of Ab, and they go on to study molecules that inhibit formation
of Ab oligomers. In a recent study using small-molecule microar-
rays (Chen et al., 2010), 79 compounds were discovered that
rescue cells from cytotoxicity. The authors suggested that
a mechanism of rescue is that a compound can accelerate Ab
aggregation past an early-forming toxic oligomer. Screening
for compounds that inhibit fibrils of tau is also an active area
(Pickhardt et al., 2005). Despite this huge effort, we are unaware
of compounds that have yet been found to be efficacious in treat-
ing Alzheimer’s disease.
A third approach uses the self-assembling property of amyloid
fibers to poison the growth of amyloid fiberswith peptides (Sciar-
retta et al., 2006). A biological system which apparently uses this
strategy is Het-S, a native inhibitor of the HET-s prion (Wasmer
et al., 2008). Adoption of this principle for chemical design is
based on our understanding that b sheets are the fundamental
organizing principle of amyloid fibrils and that fibrils grow by
addition of new strands to the sheets. The fiber is poisoned or
‘‘capped’’ by adding a peptide that acts as a new strand via
hydrogen bonding to the sheet at the fibril’s growing edge but
prevents the subsequent addition of another amyloid molecule.
Early on it was shown that the segment of Ab with sequence
KLVFF inhibits Ab aggregation (Tjernberg et al., 1996), but this
peptide itself forms steric-zipper fibrils (Colletier et al., 2011).
More recent work has emphasized modifications of the blocking
peptide, both to inhibit fibrillation of the target protein and to
prevent self-fibrillation of the blocker (for review, see Sciarretta
et al., 2006). Depending on the system, it has been found that
blocking fiber formation could either increase or diminish the
concentration of toxic oligomers (Sciarretta et al., 2006). A
protein domain that has been found to inhibit fiber assembly of
Ab is the N-terminal domain of myelin basic protein (Liao et al.,
2010).
The fourth approach is a variation of the third: inhibit fiber
growth by the structure-based design of peptides targeted to
block the ends of fibrils. This approach has become possible
by the determination of the atomic structures of steric zippers,
and it has been shown to be effective for inhibition in vitro of
two different amyloid fibers (Sievers et al., 2011). Based on the
structure of the steric-zipper segment of the tau protein with
sequence VQIVYK, an all-D-amino acid inhibitor was designed
to cap the ends of VQIVYK fibrils. This 6 residue all-D peptide
was found to inhibit fibrillation of both VQIVYK fibers and
constructs of tau. The fact that this blocker designed to cap
steric zippers also blocks fibrillation of the parent protein of the
zipper strengthens the hypothesis that steric zippers form the
essential spine of amyloid fibrils.
Biological Interventions
Amyloid formation depends on the concentration of the amyloid-
forming proteins. Thus, inhibition of the generation of amyloido-
genic proteins or of their precursors is a primary therapeutic
strategy. For example, suppression of the inflammatory process
responsible for serum amyloid A protein (SAA) overproduction is
a therapeutic option for AA amyloid and elimination of B cell
clones that overproduce immunoglobulin light chains represents
a therapeutic option for AL amyloid (Pepys, 2001). Likewise,
genetic variability in the expression of amyloidogenic proteins
at slightly higher levels than normal may contribute to the risk
of amyloidoses (Singleton et al., 2004). However, because of
the incomplete mechanistic understanding of such genetic vari-
ability, no therapeutic strategies to reduce protein expression at
the genetic levels have so far been developed.
Some amyloid-forming proteins are derived from longer
precursor proteins that need cleavage to become amyloido-
genic. The best-known example is AbPP that is sequentially
cleaved by b-secretase and g-secretase to release the Ab
peptide (De Strooper, 2010). Secretase inhibitors are currently
in clinical trials, but current inhibitors may need refinement to
avoid unwanted side effects, i.e., blocking cleavage to other
substrates (De Strooper, 2010). Other amyloids (e.g., AA,
AApoAII, and ACys) also consist of protein fragments of larger
precursors; however, it is not always clear whether such frag-
mentation is necessary for the amyloidoses or whether trunca-
tion is a secondary event without physiological significance
(Westermark, 2005). While the relationship between posttransla-
tional modification of amyloids and disease pathogenesis in
general remains ill defined, inhibiting pyroglutamyl formation is
pursued as a therapeutic target for Alzheimer’s disease (Schilling
et al., 2008).
The finding that vaccination of AbPP-transgenic mice can
prevent and reduce cerebral b amyloidosis has stimulated the
development of antibody-based immunotherapeutics for
Alzheimer’s disease (Brody and Holtzman, 2008). Although
mechanistically still unclear, antibodies directed toward Ab
gain access to the brain where they bind to soluble and/or
deposited Ab species and promote their degradation. Phagocy-
tosis of microglia as well as other mechanisms have been
proposed for amyloid removal (Brody and Holtzman, 2008).
Subsequent human immunotherapy trials showed also a reduc-tion of Ab deposits in brains of Alzheimer’s disease patients, as
predicted from the preclinical mouse work (Jucker, 2010).
However, unwanted side effects and lack of cognitive improve-
ments in ‘‘immunized’’ Alzheimer’s disease patients must be
overcome in future trials by early preventative, rather than
therapeutic, interventions (Golde et al., 2011; Selkoe, 2011).
Immunization against other amyloids, such as PrPsc, Tau, and
a-synuclein have also been reported in transgenic mouse
models (Aguzzi and O’Connor, 2010; Chai et al., 2011; Masliah
et al., 2011). Along the same line, immunological depletion (in
addition to pharmacological depletion) of serum amyloid
P component (SAP) has been developed as a therapeutic
strategy. SAP is claimed to stabilize amyloid fibrils and to be
associated with most amyloids (Bodin et al., 2010; Pepys
et al., 2002).
Are Amyloid Diseases Transmissible?
In vitro assembly of amyloid fibrils can be initiated or accelerated
by the addition of an amyloid seed (nucleus). Although originally
suggested for PrP and Ab (Jarrett and Lansbury, 1993), nucle-
ated protein aggregation is likely a phenomenon that is common
to all amyloids. Thus, from the view of a structural biologist, the
features that define the amyloid state, in themselves render
amyloids as ‘‘transmissible,’’ i.e., an amyloid nucleus can
template the aggregation of a homologous protein. Neverthe-
less, only prions have unequivocally been shown to be infectious
at the level of organisms, in which an exogenous, proteinaceous
agent (the prion) initiates disease (Aguzzi and Rajendran, 2009).
Why is this, and are we sure that infectivity at the organism level
is restricted to prions?
A prion-like infectious cycle has been reported for AA
amyloid (Westermark and Westermark, 2010). AA amyloid can
be transmitted to susceptible hosts through a variety of inocu-
lation routes. Transmission of AA amyloidosis between organ-
isms (horizontal transmission, or ‘‘infectivity’’ in the view of
microbiologists) has not been proven unequivocally, but it
appears to occur in captive cheetahs through fecal-oral trans-
mission (Zhang et al., 2008). For mouse ApoAII amyloidosis,
mother-to-offspring transmission (vertical transmission) has
been demonstrated under experimental conditions (Korenaga
et al., 2006).
In age-related neurodegenerative diseases, such as Alz-
heimer’s disease and Parkinson’s disease, disease-specific pro-
teopathic deposits occur in predictable region-specific and
temporal patterns (Jucker andWalker, 2011). Such observations
raise the possibility that the occurrence of the deposits occurs
via prion-like propagation and spreading. Indeed, intracerebral
inoculation of young, human-sequence AbPP-transgenic mice
with brain extract from Alzheimer’s disease patients or aged
AbPP-transgenic mice induces b amyloidosis in a time- and
concentration-dependent manner. The induced Ab deposits first
occur in the inoculated brain region and then spread into neigh-
boring areas often along anatomical and neuronal pathways.
After prolonged incubation periods b amyloid induction spreads
throughout most of the entire brain (Hamaguchi et al., 2012;
Jucker and Walker, 2011). The amyloid-inducing factor in the
brain extract is likely aggregated Ab in a conformation or poly-
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synthetic Ab appears not to show comparable seeding activity
in vivo (Langer et al., 2011; Meyer-Luehmann et al., 2006).
Similar inoculation experiments have also been performed with
a-synuclein- and tau-containing brain extracts; indeed, prion-
like propagation spreading of the induced lesions in susceptible
mice has also been suggested (Clavaguera et al., 2009; Mouge-
not et al., 2011). The mechanism by which intracytoplasmic
lesions propagate remains puzzling, and its elucidation may
provide new insights into basic cell biological processes (Aguzzi
and Rajendran, 2009).
More recently, it has been shown that Ab-containing
brain extract can also induce cerebral b amyloidosis if the ex-
tract is applied intraperitoneally (Eisele et al., 2010). These
remarkable findings imply that the proteopathic seed can travel
from the periphery to the brain. AA amyloid also has been sug-
gested to spread among organs, possibly via the blood (Wester-
mark and Westermark, 2010). Thus, in susceptible hosts and
under experimental conditions, transmission, propagation, and
spreading of amyloid seeds within and between organs appear
to be possible.
Because of the unusual nature of proteopathic agents and
their obligatory relationships to the host, the infectivity of
protein-based diseases between individuals is refractory to veri-
fication by Koch’s postulates, which were designed to assess
the infectivity of microbes (Walker et al., 2006). Hence, it has
been suggested that the postulates be modified to account for
the physicochemical characteristics of the infectious protein
and to recognize the importance of the host in governing
susceptibility to the disease (Walker et al., 2006). Naturally,
epidemiological evidence also should be brought to bear on
this issue. According to these criteria, compelling evidence for
the infectivity of prion diseases has been presented (Colby and
Prusiner, 2011), but for nonprion amyloidoses such evidence is
still largely lacking. Thus, in future studies, there is a need for
the epidemiological assessment of the relevance of the experi-
mental amyloid transmission studies. Moreover, there is
a need to study host susceptibility traits that allow proteopathic
seeds to become ‘‘infectious.’’ It may well turn out that, although
mechanistically similar to prionoses at the molecular level, the
susceptibility of humans to the horizontal transmission of nonp-
rion amyloid diseases is clinically insignificant under normal
conditions. Nevertheless, the remarkable prevalence of this
pathogenic principle suggests that common therapeutic strate-
gies might be directed toward a variety of currently untreatable
diseases.
Outlook
Although the research reviewed here, constrained by space limi-
tations, portrays only part of the rapidly advancing knowledge
about amyloid diseases, it may be sufficient to define some of
the critical questions for the next phase of work.
At the molecular level, we still lack high resolution knowledge
of amyloid oligomers in all but the simplest fibers. Recent work
has begun to reveal the structural basis of prion strains. Now
we need to establish whether amyloid strains play a physiologi-
cally significant role in other amyloid diseases, and, if so, we
need a fuller view of amyloid polymorphism. Furthermore, we
need a better molecular understanding of the assembly path-1198 Cell 148, March 16, 2012 ª2012 Elsevier Inc.ways from functional proteins to amyloid oligomers and fibers
and their pathways for disassembly. At the level of cellular
biology, we need to learn which biological cofactors stabilize
and destabilize amyloid structures, and we need to fill in more
details of metabolic and signaling pathways that regulate degra-
dation and disposal of amyloids.
An urgent need is the further development of structural
and physiochemical techniques that permit the analysis of
aggregated proteins in cells and living tissues, as opposed
to extracted amyloid or recombinant amyloid. A remaining
mystery is the enormously greater potency of seeding by
amyloid and prions extracted from tissues compared to re-
combinant amyloids. Is this greater potency due to undetected
biological cofactors in the extracted material, or has the ex-
tracted protein been templated into some structure in vivo
which the recombinant, apparently identical, material cannot
achieve? Can biological factors be discovered which can
convert recombinant proteins to forms that are as potent as
extracted amyloid?
Another mystery involves the mechanisms and pathways for
cellular toxicity of amyloid. Are there common mechanisms of
toxicities, or do mechanisms differ between systemic and
cerebral amyloid diseases? What are the toxic structures? Are
oligomers distinct from small fibers, and what accounts for their
toxicity? Why can toxicity of PrP be recapitulated in animal
models whereas the toxicity of Ab in animal models is compara-
tively modest? What is different about functional amyloids that
render them nontoxic?
Finally, the implications for disease of the recently reported
experimental transmission of nonprion amyloids need to be es-
tablished. Are similar or different structures responsible for
toxicity and transmission? Can amyloid in the environment
seed human diseases, and, if so, what protective measures are
necessary?
As answers to these questions emerge, a class of diseases
that afflict and kill millions will be understood and perhaps
controlled by preventative and therapeutic interventions.ACKNOWLEDGMENTS
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